BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, announced a Master Clinical Research Collaboration Agreement with the Abramson Cancer Center (ACC) of the University of Pennsylvania to support multiple research projects at the cancer center.
The first research project to arise from this collaboration aims to support clinical research focusing on personalized cancer vaccines, a new approach of active immunotherapy which utilizes the patient’s own immune system to identify tumor specific neoantigens. BostonGene’s advanced computational algorithms will identify cancer specific neoantigens and profile the immune activation status of the tumor by performing advanced multi-omics analysis, including the interpretation and visualization of cancer patient’s genomic, transcriptomic and imaging datasets. The analysis includes the identification of targetable molecular alterations, evaluation of gene expression and gene signatures, characterization of cellular components in the tumor microenvironment, estimation of tumor heterogeneity, prediction of neoantigens and tumor clonality.
“BostonGene’s strategy is to revolutionize medicine in the quest to identify better, personalized treatment options with successful outcomes,” said Andrew Feinberg, President and CEO at BostonGene. “We are pleased to support the Abramson Cancer Center by providing sophisticated analytics and integration of scientific and clinical knowledge in an effort to improve the standard of care and redefine the treatment selection approach for cancer patients.”
The ACC, a global leader in basic, translational, clinical, and biomedical research for the advancement of cancer care, is a matrix cancer center embedded within the University of Pennsylvania and the University of Pennsylvania Health System. The ACC, a National Cancer Institute-Designated Comprehensive Cancer Center, is comprised of cancer specialists committed to offering cancer patients the newest and most innovative therapeutic advances.
“We look forward to using BostonGene’s technology to help in our work to better understand the mechanisms of cancer neoantigen recognition and to the discovery of new immunotherapy treatment options,” said Gerald Linette, MD, PhD, a professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania and Clinical Director of the Parker Institute for Cancer Immunotherapy at Penn. “We are excited about this collaboration, and with our combined expertise have an opportunity to make a profound impact on how cancer patients are treated in the future.“